Study to Evaluate Efficacy of OLX10010 in Reducing Recurrence of Hypertrophic Scarring After Scar Revision Surgery

NCT ID: NCT04877756

Last Updated: 2024-02-21

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 22 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-08-19
• Study Completion Date: 2023-07-12

Brief Summary

Phase 2a, prospective, randomized, double-blind, intra-subject, placebo-controlled, proof of concept study. Approximately twenty subjects will be randomized 1:1 to one of two treatment arms:

Arm A: 2.0 mg/cm OLX10010 biweekly (every two weeks) Arm B: 5.0 mg/cm OLX10010 biweekly (every two weeks) Each treatment arm will have approximately 10 subjects. Each subject will receive both active (OLX10010) and control (placebo) treatment post-hypertrophic scar surgery biweekly (every two weeks) for a total of six doses. Dosing will occur post-surgery on Weeks 2, 4, 6, 8, 10, and 12. Post-treatment follow-up visits will occur at Weeks 18 and 24, and a long-term follow-up visit will occur at Month 12. The Patient and Observer Scar Assessment Scale (both physician and patient scales), Stony Brook Scar Evaluation Scale, Vancouver Scar Scale, and a photograph-based visual analog scale by blinded experts will be completed prior to scar revision surgery, at Weeks 2, 8, 12, 18, and 24, and at Month 12. The overall opinion responses on the physician scales of the POSAS at Week 24 will be used for primary endpoint analysis.

The total length of the linear hypertrophic scar line will be divided equally for treatment with OLX10010 and placebo, injected intradermally per centimeter (cm). The OLX10010 end and placebo end of the scar line will be separated by a 2 cm or greater distance depending on the scar length.

After the Week 24 visit, all data collected will be cleaned and all data management activities will be completed. After the database is frozen/locked, the primary endpoint efficacy analysis will be completed. If at least one of the treatment arms are shown to be appropriate to reduce recurrence of hypertrophic scars, all analyses will be performed. If the efficacy analysis of Arms A and B indicate the study doses are not as effective as expected, the sponsor may decide to add a third arm (Arm C) to explore the weekly dosing regimen. See detailed summary.

Subjects in all study arms will continue in the study until their Month 12 visit. After all subjects complete that visit, data are collected, and data management activities are completed, Month 12 data will be analyzed.

Detailed Description

This is a Phase 2a, prospective, randomized, double-blind, intra-subject, placebo-controlled, proof of concept study. Approximately twenty subjects will be randomized 1:1 to one of two treatment arms:

Arm A: 2.0 mg/cm OLX10010 biweekly (every two weeks) Arm B: 5.0 mg/cm OLX10010 biweekly (every two weeks) Each treatment arm will have approximately 10 subjects. Each subject will receive both active (OLX10010) and control (placebo) treatment post-hypertrophic scar surgery biweekly (every two weeks) for a total of six doses. Dosing will occur post-surgery on Weeks 2, 4, 6, 8, 10, and 12. Post-treatment follow-up visits will occur at Weeks 18 and 24, and a long-term follow-up visit will occur at Month 12. The Patient and Observer Scar Assessment Scale (both physician and patient scales), Stony Brook Scar Evaluation Scale, Vancouver Scar Scale, and a photograph-based visual analog scale by blinded experts will be completed prior to scar revision surgery, at Weeks 2, 8, 12, 18, and 24, and at Month 12. The overall opinion responses on the physician scales of the POSAS at Week 24 will be used for primary endpoint analysis.

The total length of the linear hypertrophic scar line will be divided equally for treatment with OLX10010 and placebo, injected intradermally per centimeter (cm). The OLX10010 end and placebo end of the scar line will be separated by a distance of 2 cm or greater depending on the scar length.

After the Week 24 visit, all data collected will be cleaned and all data management activities will be completed. After the database is frozen/locked, the primary endpoint efficacy analysis will be completed. If at least one of the treatment arms are shown to be appropriate to reduce recurrence of hypertrophic scars, all analyses will be performed. If the efficacy analysis of Arms A and B indicate the study doses are not as effective as expected, the sponsor may decide to add a third arm (Arm C) to explore the weekly dosing regimen:

Arm C: 2.0 mg/cm OLX10010 weekly If added, Arm C will enroll 10 subjects. Each subject will receive both active (OLX10010) and control (placebo) treatment post-hypertrophic scar surgery weekly for a total of 11 doses. Dosing will occur post-surgery on Weeks 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12. Post-treatment follow-up visits will occur on Weeks 18 and 24, and a long-term follow-up visit will occur at Month 12. The Patient and Observer Scar Assessment Scale (both physician and patient scales), Stony Brook Scar Evaluation Scale, Vancouver Scar Scale, and a photograph-based visual analog scale by two blinded independent assessors will be completed prior to scar revision surgery, at Weeks 2, 8, 12, 18, and 24, and at Month 12. The overall opinion responses on the physician scales of the POSAS at Week 24 will be used for primary endpoint analysis. After all subjects in Arm C complete Week 24, all data are collected, and all data management activities are completed, a new database freeze/lock will be performed. Arm C data will be analyzed.

Subjects in all study arms will continue in the study until their Month 12 visit. After all subjects complete that visit, data are collected, and data management activities are completed, Month 12 data will be analyzed.

Conditions

Hypertrophic Scar

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: QUADRUPLE

Study Groups

Arm A 2.0 mg/cm OLX10010 biweekly

Arm A- half the scar treated with 2.0 mg/cm of OLX10010 biweekly, other half treated with OLX Placebo

Group Type: EXPERIMENTAL

OLX10010

Intervention Type: DRUG

Lyophilized cake reconstituted with WFI and injected intradermally

Arm B 5.0 mg/cm OLX10010 biweekly

Arm B- half the scar treated with 5.0 mg/cm of OLX10010 biweekly, other half treated with OLX Placebo

Group Type: EXPERIMENTAL

OLX10010

Intervention Type: DRUG

Lyophilized cake reconstituted with WFI and injected intradermally

Arm C 2.0 mg/cm OLX10010 weekly

Arm C- half the scar treated with 2.0 mg/cm of OLX10010 weekly, other half treated with OLX Placebo

Group Type: EXPERIMENTAL

OLX10010

Intervention Type: DRUG

Lyophilized cake reconstituted with WFI and injected intradermally

Interventions

OLX10010

Lyophilized cake reconstituted with WFI and injected intradermally

Intervention Type: DRUG

Other Intervention Names

a cell penetrating asymmetric small interference RNA (cp-asiRNA), targeting a gene involved in formation of fibrosis

Eligibility Criteria

Inclusion Criteria

• Healthy males or females, aged 18 to 65, inclusive
• Hypertrophic scar in the abdominal region, from previous surgery or injury, present for ≥ 12 months
• Linear hypertrophic scar equal to or greater than 8 cm in length
• Undergoing elective hypertrophic scar revision surgery
• Serum pregnancy test negative for females of childbearing potential
• Males and females of child-bearing potential (e.g., not post-menopausal for at least one year or surgically sterile) must agree to use effective contraception starting at the Screening Visit and continuing until 14 days after the last dose of OLX10010.
• Properly obtained written informed consent

Exclusion Criteria

• BMI greater than 32 kg/m2. Exceptions to this criteria can be granted for patients just over this value per PI's discretion
• Hypertrophic scars outside the abdominal area, including face, neck, back, limbs, and the thoracic region
• Hypertrophic scar secondary to burns
• Active infection near the scar revision surgery
• Clinically significant wound near the scar revision surgery
• Additional scar(s) within 2 cm of the scar revision surgery
• End-stage renal disease or severe renal impairment as indicated by serum creatinine > 2.5 mg/dL
• Hypertrophic scar treatment within 12 weeks prior to the screening visit, excluding scar revision surgery
• Radiation or chemotherapy within 12 weeks prior to the screening visit
• Treatment with anti-psychotic, anti-cancer, immunosuppressant, or corticosteroids within 12 weeks prior to the screening visit
• Atopic dermatitis, keloid scar, or skin hypersensitivity
• Received elective body sculpting procedures (e.g., CoolSculpting®) for the abdomen within the past 6 months
• Use of tobacco or nicotine-containing products during study participation (Screening Visit through last follow-up visit)
• Female patients who are pregnant or breastfeeding
• Participation in any experimental drug or device study within 30 days prior to the screening visit
• Any clinically significant finding, in the judgement of the treating investigator, that would place the subject at health risk, impact the study, or affect the completion of the study.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Alira Health

OTHER

Sponsor Role: collaborator

Olix Pharmaceuticals, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Alexander Neumeister, MD

Role: STUDY_DIRECTOR

OliX Pharmaceuticals

Locations

MedStar Health Research Institute

Washington D.C., District of Columbia, United States

Miami Dermatology & Laser Research, LLC

Miami, Florida, United States

Miami Plastic Surgery

Miami, Florida, United States

Henry Ford Health System

Detroit, Michigan, United States

University Hospitals Cleveland Medical Center

Cleveland, Ohio, United States

Paddington Testing Co, Inc.

Philadelphia, Pennsylvania, United States

Countries

United States

References

Hwang J, Chang C, Kim JH, Oh CT, Lee HN, Lee C, Oh D, Lee C, Kim B, Hong SW, Lee DK. Development of Cell-Penetrating Asymmetric Interfering RNA Targeting Connective Tissue Growth Factor. J Invest Dermatol. 2016 Nov;136(11):2305-2313. doi: 10.1016/j.jid.2016.06.626. Epub 2016 Jul 15.

Reference Type: BACKGROUND

PMID: 27427487 (View on PubMed)

Other Identifiers

OLX10010-02

Identifier Type: -

Identifier Source: org_study_id